Subclinical Hypothyroidism and Mind in the Elderly
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Some recommendations of expert consensus on subclinical hypothyroidism (SH) are controversial
in those areas with not enough information to reach a conclusion, such as not recommending
treatment with thyrotrophic hormone of 4-10 mUI/L and free thyroxin in normal range. The body
changes or symptoms at this stage are often mistaken as aging. There are studies showing
significant changes in heart (slow rate, lower ejection fraction, diastolic dysfunction);
hypercholesterolemia, dysfunction cognitive abilities (memory attention…).
The prevalence of SH increases with age, reaching 14% over 65 years old. This age group
increase as the population ages highlights the need for evidence to improve recommendations
for the elderly.
NEUROPSI is a validated neuropsychological test sensible for mild cognitive alterations. It
can be applied to individuals with little schooling.
This study aims to determine positive change in cognitive abilities (NEUROPSI), ejection
fraction, and body percent of lean and adipose tissue without adverse effects, placebo versus
thyroxin supplement to keep thyroid-stimulating hormone (TSH) between 0.5-2.5 mUI/L in
elderly with TSH 4-10 mIU/L.